

[For Immediate Release]

The logo for EuroEyes, featuring the word "EuroEyes" in white sans-serif font on a dark blue rectangular background.

**EuroEyes International Eye Clinic Limited**

德視佳國際眼科有限公司

(Stock Code: 1846.HK)

**EuroEyes 2025 Annual Results**  
**Revenue Hits Another Record High of HK\$769mn**  
*Fueled by Sustained Presbyopia Treatment Growth and  
Strategic Progress in M&A Execution*

(Hong Kong, 31 March 2026) - [EuroEyes International Eye Clinic Limited](#) (“EuroEyes” or the “Company”, together with its subsidiaries, the “Group”, stock code: 1846), a leading global vision correction service provider, today announced its annual results for the year ended 31 December 2025 (“2025” or the “Year”), highlighted by revenue increase for the seventh consecutive time since going public.

**Achieves Record Revenue Amid Strong Presbyopia Demand**

During the Year, the Group achieved a revenue increase for the seventh consecutive time since going public, reaching another record high of HK\$796.0 million, marking an 11.2% increase year-on-year. Excluding the contribution from the Swiss Acquisition, organic revenue increased by 9.6% year-over-year, reaching HK\$784.2 million. Gross profit rose by 13.2% to HK\$324.3 million from 2024 with gross profit margin stood at 40.7%. Excluding the impact of the Swiss Acquisition, the organic gross profit increased by 12.9% to HK\$323.4 million, with organic gross profit margin reaching 41.2%. During the Year, EuroEyes successfully conducted 28,109 eye surgeries, an increase from 27,045 procedures performed in the previous year.

EuroEyes’ EBITDA increased by 6.3% year-on-year, reaching HK\$242.3 million. The EBITDA margin experienced a slight decline to 30.4%; however, on an organic basis without the Swiss Acquisition, the margin improved to 32.2%. Net profit attributable to the Company’s equity holders decreased by 33.8% year-on-year to HK\$54.5 million. When excluding the Swiss Acquisition impact, the organic net profit attributable to equity holders declined by 11.9% to HK\$72.5 million. This reduction in organic net profit was primarily due to an unrealized foreign exchange loss arising from the mark-to-market revaluation of certain Euros denominated intercompany payables due to the appreciation of the EUR against the RMB. It should be noted that this loss is non-cash and remains unrealized.

To share the profit with shareholders, the Directors recommended a final dividend of HK\$0.0126 per ordinary share for the year ended 31 December 2025. Together with the interim dividend of HK\$0.0315 per ordinary share, the total dividend for the Year amounted to HK\$0.0441, representing a dividend payout ratio at 25%.

### **Enhanced Market Leadership in Presbyopia Treatments**

Lens exchange surgery accounted for 56.4% of the Group's total revenue, up from 54.6% last year. During the Year, revenue from lens exchange procedures, mainly involving trifocal lenses for presbyopia correction, increased by 14.8% compared to the previous year, reaching a record HK\$448.8 million. This robust growth was driven by the ageing populations across the countries where EuroEyes operates. As part of the natural ageing process, surgery offers the most effective solution for replacing reading glasses, resulting in steady demand for presbyopia correction treatments that remain strong even in challenging economic environments.

In addition to offering lens exchange surgery, the Group also provides Presbyond, a refractive laser treatment for presbyopia. This innovative procedure was made available to the Group's international patients in Germany and the PRC beginning in 2023. Presbyond now accounts for 4.8% of the Group's total revenue, an increase from 4.2% last year, contributing HK\$38.2 million to the Group's earnings for the Year, marking a 26.1% growth compared to the previous year.

By combining these two treatments, the presbyopia segment represented 61.2% of the Group's total revenue, amounting to HK\$487.0 million.

### **Executed M&A strategy successfully**

The Group has successfully executed its mergers and acquisitions strategy, completing one add-on acquisition in Switzerland during the Fiscal Year and pursuing a strategic acquisition in the Netherlands, which was announced in February 2026. The Swiss acquisition, finalized in mid-October 2025, aims to introduce advanced myopia and innovative presbyopia treatments to the market. The operations under the Swiss Acquisition were rebranded as the Company's operations on closing, effectively a relaunch of the business. With eight clinics across Switzerland, the Group now offers high-end myopia treatments and innovative presbyopia solutions. The Group has significantly streamlined operations and implemented a new marketing strategy to drive growth. The impact of these initiatives is anticipated to materialize by mid-FY2026. Meanwhile, the NL Acquisition is currently awaiting Shareholder approval and is projected to be consolidated into the Group's financial statements in the second half of FY2026, significantly enhancing the Group's scale and profitability.

Regarding other merger and acquisition opportunities, EuroEyes remains actively open to exploring suitable prospects as they become available.

### **Geographically Diversified Operations to Address Forthcoming Challenges**

With operations stretching from Europe to Asia, EuroEyes benefits from a geographically diversified revenue base that helps balance its overall performance.

In Germany, total revenue reached HK\$426.8 million, accounting for 53.6% of the Group's overall revenue. The strong growth was primarily driven by increased demand for presbyopia treatments. Revenue from lens exchange surgery and Presbyond surgery in Germany rose to HK\$248.8 million and HK\$7.3 million, representing year-on-year growth of 12.2% and 102.8%, respectively. Additionally, the Group observed a positive resurgence in demand for myopia treatments, with revenue from refractive laser surgery increasing by 8.7% year-over-year to HK\$117.9 million.

In the PRC, EuroEyes demonstrated strong resilience in the face of persistent macroeconomic headwinds and subdued consumer confidence. Despite these challenges, the Group achieved a

steady year-over-year revenue growth of 0.5%, driving regional sales to HK\$146.1 million. Notably, even amid a difficult economic environment, it saw significant growth in presbyopia treatments, including lens exchange and Presbyond surgeries, which helped to counterbalance the challenges encountered in the country's highly competitive myopia market.

The UK operation continued to be a key driver of the Group's growth during the Year. The flagship clinic in Knightsbridge, renowned for lens exchange surgeries, benefited from strong demand for presbyopia treatments. Meanwhile, the London Vision Clinic experienced a renewed increase in demand for myopia treatments. Both clinics contributed to the UK's total revenue reaching HK\$134.5 million, representing an 18.7% year-over-year increase.

In Denmark, EuroEyes' new marketing initiatives contributed to a strong recovery, resulting in a 7.1% year-over-year increase in annual revenue, reaching HK\$76.8 million. Approximately 93.3% of sales in the country were generated from lens exchange surgeries, which experienced an 8.5% growth compared to the previous year.

**Dr. Jørn Slot Jørgensen, Founder, Chairman and CEO of EuroEyes** said, "Looking ahead, we remain cautiously optimistic that the positive recovery trends observed in 2025 will continue into the new financial year. With the completion of our two acquisitions, our immediate focus is on seamlessly integrating our newly acquired operations in Switzerland and the Netherlands to enhance operational efficiency and unlock synergies. We reiterate our three-year growth guidance, targeting a low- to mid-teens organic CAGR for revenue, high-teens for EBITDA, and low-twenties for organic net profit through 2028. This growth will be underpinned by our key pillars and global portfolio. Looking forward, we will also continue to actively evaluate suitable M&A opportunities that can further bolster our growth trajectory."

-End-

#### **About EuroEyes International Eye Clinic Limited (1846.HK)**

EuroEyes was established in 1993 by Dr Jørn Jørgensen, an internationally recognized refractive surgeon and entrepreneur and today is one of the leading brands in the vision correction industry that combines German ophthalmology excellence and over 30 years of experience with individualised patient care. EuroEyes is one of the few eye clinic groups with a far-reaching geographical coverage, with operations in Germany, Switzerland, Denmark, the PRC and the United Kingdom. The Group's vision correction services include (i) refractive laser surgery (which includes ReLEx smile and Femto LASIK and Presbyond®); (ii) phakic lens (ICL) surgery; (iii) lens exchange surgery (which includes the monofocal and trifocal lens exchange surgery) and (iv) others (which include PRK/LASEK and ICRS implantation). For more information, please visit [ir.euroeyes.hk](http://ir.euroeyes.hk).